The activity of androgen-deprivation therapy (ADT) in androgen receptor-positive (AR+) salivary gland carcinomas (SGCs) has been established in the past few years. Second-line treatment in castration-resistant patients is still unknown. We investigated the activity of abiraterone acetate as second-line treatment in ADT-resistant, AR+ patients with SGC.
Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial
Bossi, Paolo;
2021-01-01
Abstract
The activity of androgen-deprivation therapy (ADT) in androgen receptor-positive (AR+) salivary gland carcinomas (SGCs) has been established in the past few years. Second-line treatment in castration-resistant patients is still unknown. We investigated the activity of abiraterone acetate as second-line treatment in ADT-resistant, AR+ patients with SGC.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
PMID 34597119 Abiraterone Acetate in Patients With Castration.pdf
accesso aperto
Descrizione: Abiraterone Acetate in Patients With Castration
Tipologia:
Full Text
Licenza:
DRM non definito
Dimensione
724.77 kB
Formato
Adobe PDF
|
724.77 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
